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Rationale: Fragile histidine triad (FHIT) is a tumor suppressor gene
involved in the pathogenesis of lung cancer.
Objectives: The purpose of this studywas to investigate the different
molecular alterations leading to the inactivation of FHIT gene
function and to validate their use as biomarkers of risk for pro-
gression of the disease in patients belonging to the multicentric
European study for the Early detection of Lung Cancer (EUELC) who
were resected for early-stage lung tumors.
Methods: FHIT immunostaining was performed on 305 tumor sam-
ples. Themethylation status of FHITpromoterwas assessedbynested
methylation-specific polymerase chain reaction (MSP-PCR) in 232
tumor and 225 normal lung samples ofwhich a subset of 187 patients
had available normal/tumorDNApairs. Loss of heterozygosity (LOH)
at the FHIT locus was analyzed in 202 informative cases by D3S1300
and D3S1234 microsatellite markers.
Measurements and Main Results: Lost or reduced FHIT expression was
found in 36.7 and 75.7% of the tumor samples, respectively. Meth-
ylation of the FHITpromoterwas found in 36.7%of tumor and 32.7%
of normal lung samples, whereas LOH was detected in 61.9% of the
tumors. A strong association with complete loss of FHIT expression
waspresentwhenmethylation and LOHwere analyzed together (P5
0.0064). Loss of FHIT protein expression was significantly more
frequent in squamous cell carcinoma histotype (P , 0.0001) and in
smokers (P5 0.008). FHITmethylation in normal lungwas associated
with an increased risk of progressive disease (OR, 2.27; P5 0.0415).
Conclusions:Our results indicate thatdifferentmolecularmechanisms
interplay to inactivate FHIT expression and support the proposition
that FHIT methylation in normal lung tissue could represent a prog-
nostic marker for progressive disease.
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Lung cancer is one of the most common malignancies in the
world and represents the leading cause of cancer-related deaths
in industrialized countries. The overall 5-year survival rate for
lung cancer is less then 15% largely due to the late stage at
which most patients are diagnosed. Because survival of patients
surgically resected for early-stage lung cancer is variable, the
detection of additional prognostic parameters could be of
importance to better predict the outcome of the disease and
to offer the optimal therapeutic treatment to the patients.
Fragile histidine triad (FHIT) is a tumor suppressor gene that
spans the FRAB3B common fragile site at chromosome 3p14.2
and is frequently altered in lung cancer (1). Restoration of FHIT
expression in cell lines lacking endogenous protein restrains
tumor formation in vivo and in vitro through induction of
apoptosis and inhibition of cell cycle progression (2). Homozy-
gous deletions and loss of heterozygosity (LOH) at the FHIT
locus have been frequently reported in lung cancer cell lines and
primary tumors (3–7); aberrant FHIT mRNA transcripts have
been detected in 40 to 80% of tumor samples (8), whereas
mutations are rare. Loss of FHIT protein expression is observed
in almost 70% of primary tumors, mainly in those arising in
smokers, and in 90% of preinvasive lesions (9). The promoter
region around exon 1/intron 1 of the FHIT gene contains CpG
islands that have been shown to be hypermethylated in lung
cancer and methylation was associated with loss of FHIT mRNA
and protein expression (10, 11). Promoter methylation is critical
for regulation of FHIT expression insofar as treatment with
5-aza-29-deoxycytidine restores the unmethylated status of the
FHIT promoter and the reexpression of FHIT mRNA in epithe-
lial cell lines (12).
To dissect the contribution of the different biological mech-
anisms leading to FHIT gene inactivation we looked at the
association among molecular alterations (LOH and promoter
methylation) and FHIT protein expression in a large series of
early-stage lung tumors with prolonged follow-up collected in
the multicentric European study for the Early detection of Lung
Cancer. Hypermethylation of the FHIT promoter was also
evaluated in normal lung of these patients, and the association
between FHIT alterations in tumors and normal lung and the
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
The loss of fragile histidine triad (FHIT) protein expres-
sion was frequently observed in primary non–small cell
lung cancer. The FHIT gene function is inactivated by
different biological mechanisms as promoter methylation
and loss of heterozygosity at the FHIT locus.
What This Study Adds to the Field
The association between FHIT methylation in normal
tissue and prognosis suggest that FHIT methylation in
normal lung could represent a prognostic marker for early
recurrence.
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clinical outcome of the patients was studied in an attempt to
provide a molecular tool useful for identifying individuals at
higher risk of relapse or second primary tumors. Some of the
results of these studies have been previously reported in the
form of an abstract (13).
METHODS
Study Population
A cohort of individuals with a diagnosis of early stage (I-II) lung cancer
and who underwent surgical resection was included in the European
study for the Early detection of Lung Cancer (EUELC). The patients
were recruited before surgery in 12 cancer centers throughout Europe
from 2002 to 2006 and were subsequently followed-up every 6 months
for the duration of this study. Inclusion criteria are detailed in the
online supplement. Tissue and biological specimens collected were sent
from all the recruiting centers to the centralized European Bronchial
Tissue Bank (EBTB) located in Liverpool, UK. A web-based database
was set up (MACRO) to hold all clinical, epidemiological and follow-
up data, as well as information on tissue and biological specimens
collected in the study.
From the EUELC cohort of 913 patients, 359 cases were selected
for this analysis on the basis of the availability of material for molecular
analyses and clinical information for an average follow-up period of
18 months. To assess the molecular risk factors for disease progression,
the patients were classified in two groups: those with early relapse,
recurrence, metastasis, or second primary lung cancer (with a disease-
free period of 6 mo after surgery) were defined as progressive disease
group (PD); patients that remained tumor-free during the study were
defined as disease-free group (DF). The characteristics of study
population are summarized in Table 1.
Tissues Collection and DNA Extraction
All tissues were freshly collected during surgery and stored at 2808C in
the EBTB bank. As a routine practice for TNM staging nontumor lung
specimens are sampled at a distance from the tumor to guarantee that
the tissues are free from cancerous cells, atelectasis, and obstructive
pneumonia (14).
Frozen normal and tumor tissues were cut into 20 3 4 mm sections.
Tumor sections were stained with H&E and microscopically reviewed
for tumor cell content. Excessive normal tissue was removed to ensure
80% or more tumor cell content.
For LOH analysis, normal control DNA was extracted from
peripheral blood lymphocytes. DNA extraction from tissue samples
and lymphocytes was performed using DNeasy 96 Blood and Tissue kit
(Qiagen, Studio City, CA) following supplier’s protocol.
Immunohistochemistry
Immunohistochemical staining was performed on formalin fixed paraffin–
embedded biopsies with the rabbit anti-FHIT antibody (18–0219, Zymed
Laboratories, South San Francisco, CA) at a dilution of 1:100 on Ventana
automated immunostainer (Ventana, Tucson, AZ). For antigen retrieval,
5 minutes of microwave heating in ethylenediaminetetraacetic acid buffer
was repeated twice. FHIT immunoreactivity was classified according to
a score obtained by multiplying two parameters: the percentage of positive
cells (from 0 to 100) by the intensity mean level (from 0 to 3) for a global
score of 0 to 300. Normal bronchial and alveolar epithelial cells, used as
internal controls, showed a strong FHIT expression score of 200 (score 3)
or greater. An extensive loss of FHIT expression immunostaining was
considered for tumors with scores of 50 (score 1) or less, and reduced
protein expression was considered for scores of 50 to 200 (score 2). For the
purpose of statistical comparisons, a score of 0 versus 1–3 or a score of 0–1
versus 2–3, was used to obtain homogeneity of the classes and to achieve
a meaningful biological assessment.
Bisulphite Conversion and Methylation-specific Polymerase
Chain Reaction
The methylation status of the promoter region of the FHIT gene was
evaluated by methylation-specific polymerase chain reaction (MSP-
PCR) after DNA modification with sodium bisulphite (EZ DNA
Methylation Gold Kit, Zymo Research, Orange, CA (15). MSP analysis
for the FHIT gene investigates the genomic areas that represent the best
targets for functionally relevant methylation identified into intron 1 (see
online supplement for further details on METHODS).
LOH Analysis
Allelic LOH analysis at the FHIT locus on 3p14.2 was performed by
studying the combination of two microsatellite alterations, D3S1300 and
D3S1234. Thirty nanograms of DNA from tumor tissue and matching
lymphocytes were used for the analysis, as previously reported (16, 17).
Statistical Analysis
Fisher exact test was performed to test independence of variables.
Distributions of demographic variables (including sex and smoking
status) between PD cases and DF controls were evaluated by chi-
square test. Differences between PD cases and DF controls in age and
self-reported pack-years were tested using the Student’s t test. When
the data distribution significantly deviated from normal, the Wilcoxon
rank sum test was performed. Odds ratios (OR) and 95% confidence
interval (CI) were calculated as estimates of relative risk. Odds ratios
associated with each risk factor were calculated using the conditional
logistic regression model while adjusting for confounders. A test for
trends was performed by coding the categories in successive integers
and using the likelihood ratio test statistics with one degree of freedom.
Statistical analyses were performed with the statistical analysis package
SAS for Windows, version 8.02 (SAS Institute, Cary, NC).
Risk estimation for disease progression according to different
variables was initially performed on a set of patients with a 1:1 ratio
of PD:DF (n 5 176, first set). To achieve optimal matching in assessing
epidemiological and molecular risk factors for disease progression in
the final dataset (n 5 359), the conditional logistic regression for
matching design was used. PD cases and DF controls were matched
with a 1:2 ratio using the SAS language procedure (see online supple-
ment). Patients were matched on follow-up times (at least as long as the
event time for PD subjects) and also on center, sex, age (66 y),
histological subtypes, and N stage.
RESULTS
Biological Mechanisms of Inactivation of FHIT Gene and Their
Correlation with FHIT Protein Expression
From the series of 359 cases originally selected for biomarker
analysis the number of samples analyzed in each FHIT assay
TABLE 1. CHARACTERISTICS OF STUDY POPULATION
First Set Final Set
Patient Characteristic (n 5 176) (n 5 359)
Sex
Male 155 (88.1) 301 (83.8)
Female 21 (11.9) 58 (16.2)
Age, yr 63.8 6 9.2 63.9 6 9.1
Smoking history
Never-smoker 9 (5.1) 16 (4.5)
Current and former-smoker 158 (89.8) 332 (92.5)
Missing 9 (5.1) 11 (3)
Histology
Squamous carcinoma 84 (47.8) 165 (46)
Adenocarcinoma 90 (51.1) 183 (51)
Other 11 (3) 2 (1.1)
Stage
Stage I 118 (67) 232 (64.6)
Stage II or higher 55 (31.3) 121 (33.7)
Missing 3 (1.7) 6 (1.7)
Event
DF 90 (51.1) 241 (67.1)
PD 86 (48.9) 118 (32.9)
Definition of abbreviations: DF 5 disease-free group; PD 5 progressive disease
group.
Values are n (%) or mean 6 SD.
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was limited to subsets on the basis of specimen type availability in the
EBTB bank. Thus, immunohistochemistry (IHC) analysis of FHIT
protein expression was performed in 305 cases with formalin-fixed,
paraffin-embedded (FFPE) tissue, DNA for methylation analysis
was available from 232 tumor and 225 normal lung tissues, while
LOH analysis was performed in a subset of 228 tumor-normal pairs.
FHIT protein expression. Immunostaining was performed on
sections from 305 paraffin embedded tumor samples (Figure 1).
Reduced protein expression (a score of 0–2) was found in the
majority (75.7%) of the tumor samples, whereas extensive loss
of FHIT expression (a score of 0–1) was also detected in
a significant subset (36.7%). Frequencies for each score of
FHIT expression are reported in Table 2. Loss of FHIT protein
expression (a score of 0–1) was significantly higher (P , 0.0001)
in squamous cell carcinoma (82/137, 59.9%) than in adenocar-
cinoma (30/168, 17.9%), whereas expression was not associated
with pathological tumor-node-metastasis (pTNM) stage. A sig-
nificant association was observed between expression and smok-
ing habits: loss of FHIT expression was significantly greater
(P 5 0.008) in former and current smokers (221/287, 77%) than
in never-smokers (6/14, 42.9%).
FHIT promoter methylation in tumor and normal tissues.
PCR amplification was successful, as assessed by the presence
of a product in the ‘‘unmethylated’’ reaction, in 229/232 tumor
tissues and in 208/225 normal tissues. MSP demonstrated the
presence of methylated FHIT alleles in 36.7% (84/229) tumor
tissues and in 32.7% (68/208) of the normal adjacent tissues
examined, indicating a marginal but not significant increase of
FHIT methylation frequency in tumor tissue (P 5 0.0749). In
the subset of 187 patients with paired normal and tumor tissue
successfully analyzed we observed methylation in both tissues in
15% (28/187) of the pairs, whereas 46% (86/187) of the pairs
presented only unmethylated alleles (Figure 2). Although 21%
(39/187) of the pairs demonstrated FHIT methylation only in
tumor DNA, perhaps the most intriguing group was the
remaining 18% (34/187) that included cases with methylation
restricted to normal lung samples. Among the cases with
methylation in normal tissue 45.2% (28/62) showed methylation
also in the corresponding tumor sample, whereas the remaining
54.8% (34/62) was unmethylated in the matching tumor DNA
(Table 3). No significant association was observed between
FHIT methylation in tumor and normal samples or between
FHIT methylation status in normal and tumor samples and
clinical-pathological variables like smoking habits, tumor stage,
and histology.
Genomic instability of FHIT locus. LOH at the FHIT locus
at 3p14.2 was analyzed in 228 normal-tumor paired DNAs
combining two microsatellite markers: D3S1300 (intron 5) and
D3S1234 (intron 7). The analysis revealed LOH at D3S1234 in
59% (92/156) of the informative (heterozygous) cases, while for
D3S1300 56.2% (59/105) of the informative cases showed with
LOH. The combined analysis of the two microsatellites,
D3S1300 and D3S1234, resulted in 202 informative cases of
which 61.9% (125/202) showed LOH at the FHIT locus for at
least one microsatellite. As expected, there was a high fre-
quency of LOH coincidence between these two markers. In
particular, 71.2% (42/59) of ‘‘double informative samples’’
demonstrated LOH at both loci (Fisher’s exact test, P 5
0.001), which is in accordance with previous observations that
deletions affecting the FHIT locus are usually large and span
the entire gene.
FHIT methylation, FHIT LOH, and loss of expression by
immunostaining. To investigate the relationship between FHIT
expression with the potential underlying genetic (LOH at FHIT
locus) and epigenetic (promoter methylation) determinants we
comparatively analyzed data for these parameters. FHIT meth-
ylation and LOH resulted as independent events (P 5 1.0000),
confirming the notion that these two types of alterations represent
alternative molecular mechanisms of FHIT gene inactivation.
A borderline association (P 5 0.0577) was observed between
FHIT methylation and complete loss of FHIT protein expres-
sion (a score of 0). Among the methylation-negative samples,
however, 31 of 135 (23%) samples gave negative immunostain-
ing, suggesting that mechanisms of gene silencing other than
methylation should coexist.
LOH was significantly (P 5 0.0182) associated with loss of
FHIT expression (a score of 0), further supporting the relevant
role of this type of molecular event in inactivatingFHIT function.
The occurrence of both methylation and/or LOH were
highly associated with loss of FHIT protein expression (P 5
0.0064) indicating that genetic and epigenetic events concur to
functionally impair FHIT expression (Table 4).
FHIT Status and Risk for Disease Progression
The association between FHIT alterations and the risk of
progressive disease was assessed considering the clinical out-
come of patients with a disease-free period of at least 6 months
after surgery. Patients were classified in two groups: those with
early relapse, recurrence, metastasis, or second primary lung
cancer (with a disease-free period of 6 mo after surgery) were
defined as progressive disease group (PD); patients that
remained tumor-free during the study were defined disease-free
group (DF). We performed a preliminary analysis in a first set
of 176 patients and subsequently extended the analysis to
a larger dataset of 359 patients. Only 28 patients of the first
group were not included in the final dataset.
Progressive disease risk in the first set of patients. In the first
set of 176 patients, PD and DF groups were similarly represented,
Figure 1. Fragile histidine triad (FHIT) immunostaining in
lung tumor tissue. Representative immunohistochemical
analysis at magnification 203. (A and F) Loss of FHIT
expression in an adenocarcinoma contrasting with the
high expression of FHIT in bronchial epithelial cells. (B, C,
and E) Strong, medium, and low FHIT expression in
a squamous cell carcinoma, respectively. (D) Strong FHIT
expression in the bronchioloalveolar component of an
adenocarcinoma.
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with 86 (48.9%) PD (cases) and 90 (51.1%) DF (controls)
patients. All characteristics of this set of individuals are reported
in Table 1. Statistical analysis for assessing the risk of progressive
disease was performed according to epidemiological and clinical
characteristics and molecular biological markers. No association
was detected betweenFHITmethylation, LOH, or loss of protein
expression in tumors and prognosis.
We found a strong association between FHIT methylation
status in normal tissue, evaluated in 116 cases, and the pro-
gression of disease (OR, 4.30; P 5 0.01). Moreover, the
association remained significant after adjustment for smoking
duration, life condition, and primary tumor size (OR, 7.39; P 5
0.02).
Progressive disease risk in the final set of patients. The
analyses were then expanded to a larger dataset of 359 patients
having similar epidemiological and clinical characteristics. A
conditional logistic regression using matching design was per-
formed for the analysis of risk factors for progressive disease.
Each PD case was matched with two DF controls, as described
in METHODS. The matching was feasible for only 296 patients,
where PD and DF patients represented 31.8 and 68.2% of the
entire dataset, respectively. The distribution of clinical-demo-
graphic features was homogenous in PD and DF groups with
the exception of the tumor stage. In the DF group 74.5% of
tumors were stage I versus 47.4% in the PD group.
FHIT methylation in normal lung, evaluated in this cohort of
168 patients (Table 3), was significantly associated with an
increased risk of PD (OR, 2.27; P 5 0.0415), and the association
remained significant after adjustment for tumor size (OR, 2.28;
P 5 0.0435). Analysis according to histological subtypes showed
that FHIT methylation in normal lung was especially associated
with an increased risk of having disease progression in patients
with adenocarcinoma (OR, 3.54; P 5 0.0309).
Matching design analysis of this larger dataset did not
indicate a significant association between FHIT status in tumor
tissue and prognosis.
DISCUSSION
The overall goal of the EUELC project was to detect molecular-
pathological abnormalities in early-stage primary lung tumors
that would be useful for the identification of individuals at risk
of developing second primary lung cancers, metastasis, and
recurrences.
EUELC was one of the largest planned early lung cancer
projects in Europe, and it enabled the Partners to establish
protocols for assessing molecular biomarkers in early lung cancer
with the view that such biomarkers maybe used in future early
detection programs in Europe.
The purpose of the present study was to investigate the
different types of molecular alterations leading to the inactivation
of FHIT gene function and to validate their use as biomarkers of
risk for progression of the disease in high-risk individuals.
Several studies have reported the central role of theFHIT gene
in lung tumorigenesis, and loss of protein expression has been
described in several human neoplasms of epithelial origin in-
cluding lung cancer (9, 18–20). Because of the variety and
complexity of the molecular and epigenetic changes affecting the
FHIT gene, a loss or reduced FHIT protein expression, as detected
by immunohistochemistry, was suggested as the most reliable test
for detecting FHIT gene alterations. Previous studies already
showed that epigenetic events could impair FHIT gene function
in lung tumors.FHIT intron 1 CpG islands were found methylated
in 38% of lung squamous cell carcinomas and in 57% of breast
cancer DNAs and also in nonneoplastic adjacent mammary tissues
(14%) and lung tissues (8%) (21). In lung squamous cell carcino-
mas and breast tumors, an association between methylation of
FHIT promoter and protein expression was reported, confirming
a previous study that showed a significant association between
FHITmethylation status and loss ofFHIT expression by Northern
Blot and immunostaining in lung and breast cancer cell lines and
primary tumors (10). In a small study of 30 locally advanced (stage
III) lung carcinomas, no association was observed between FHIT
LOH and loss of FHIT mRNA and protein expression, whereas
methylation of the FHIT promoter correlated significantly with
loss of FHIT expression at the transcript level (22).
However, previous studies have not addressed how epige-
netic and genetic mechanisms interplay to inhibit FHIT protein
expression and inactivate FHIT gene function, nor have they
examined their association with prognosis using a large sample
of lung cancer patients.
To dissect the molecular mechanisms leading to FHIT gene
inactivation we investigated the relationship among the various
alterations of the FHIT gene: allelic losses, promoter methyla-
tion, and FHIT protein expression. The high frequency of FHIT
genetic, epigenetic, and protein alterations detected in this large
TABLE 2. FHIT PROTEIN EXPRESSION
Histotype Smoking Habits
Tumors SCC
ADC and
Other Never
Current or
FormerExpression
Score (n 5 305) (n 5 137) (n 5 168) P Value (n 5 14) (n 5 287) P Value
0 80 (26.2) 82 (59.9) 30 (17.9)
1 32 (10.5) P , 0.0001 6 (42.9) 221 (77) P 5 0.008
2 119 (39.0) 55 (40.1) 138 (82.1)
3 74 (24.3) 8 (57.1) 66 (23)
Definition of abbreviations: ADC 5 adenocarcinoma; SCC 5 squamous cell carcinoma.
Figure 2. Methylation-specific polymerase chain reaction (MSP-PCR)
for fragile histidine triad gene (FHIT) of normal/ tumor DNA pairs.
Normal (N) and tumor (T) DNA samples were analyzed by MSP.
Bisulphite-treated DNA extracted from normal lymphocytes (Linf) was
used as positive control of unmethylated-DNA specific primers (U) and
commercial in vitro methylated DNA after conversion as positive
control of methylation-specific primers (M). Negative control samples
without DNA were included for each PCR step (B1–B2).
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sample of early-stage lung tumors further supports a primary
role of FHIT in lung carcinogenesis. Moreover, loss of protein
expression was distinctive of smoke-related tumors and partic-
ularly related to squamous cell carcinoma.
A strong relationship among the combination of LOH and
methylation with FHIT protein expression was detected in this
sample. This association indicates that the mechanism of FHIT
gene inactivation consists of both deletions and methylation events
that contribute to the functional loss of expression. The lack of
statistical association between LOH and methylation suggests that
these two events independently affect FHIT expression.
So far no studies have analyzed the effects of FHIT promoter
hypermethylation in normal lung as a prognostic factor, whereas
cohypermethylation of p16 and FHIT promoters in tumor tissue
in 335 stage I NSCLC was associated with an increased risk of
recurrence and poor recurrence-free survival after surgery (23).
We observed a similar frequency of methylation in normal
lung and tumor tissue; however, 54.8% of patients with meth-
ylated FHIT in normal lung tissue lacked methylation in the
corresponding tumor. This is not surprising because evidence
supports, at a molecular level, an independent origin of multiple
preneoplastic and neoplastic lung lesions (24, 25).
The high frequency of FHIT methylation detected in normal
lung tissue of the patients in our study suggests that this type of
FHIT alteration is an early event in lung carcinogenesis that likely
reflects an early smoke-induced epigenetic damage. Moreover,
the finding that FHIT methylation in normal lung was associated
with an increased risk of progressive disease strongly suggests that
the continuous exposure to tobacco smoke creates a ‘‘permissive’’
environment of damaged tissue (‘‘field cancerization’’ effect) and
that additional genetic damage could trigger the transformation
process.
Recent data also indicate that extensive DNA damage,
manifested through double strand-breaks, could in part be re-
sponsible for the acquisition of aberrant gene promoter methyl-
ation during lung carcinogenesis. In particular a diminished DNA
repair capacity was found to be associated with an increased
methylation index in sputum from persons at risk for lung cancer
(26), supporting the hypothesis that methylation in normal lung
might also reflect inability to repair DNA breaks induced by
tobacco injury and therefore be linked to increased cancer risk.
Our finding is in agreement with previous reports showing that
the ability to identify extensive or specific patterns of genetic
changes in normal and preneoplastic tissues or sputum samples,
may provide new methods for assessing the risk in smokers of
developing invasive primary or recurrent lung cancer (27, 28).
Currently the outcome of patients that undergo resection for
stage I-II lung cancer is variable and influenced by many factors.
The identification of a biological marker linked to prognosis
that is assayable in surgical specimens could therefore provide
valuable information regarding the risk of early recurrence and
help in the clinical management of those early lung cancer
patients that might require more intensive follow-up or further
treatment.
Recently, gene-expression profiling studies in noncancerous
hepatic tissue, and subsequently in noncancerous lung tissue of
patients with early-stage adenocarcinoma, have reported a cy-
tokine gene expression signature associated with a poor prog-
nosis. These findings showed how noncancerous tissues could be
suitable specimens to identify prognostic markers for patients
who are at high risk of recurrence or metastasis (29, 30).
Thus, the final analysis on the complete dataset confirmed the
association betweenFHITmethylation in normal tissue and early
recurrence that was already detected in a preliminary analysis on
a smaller set. A statistical trend, although not significant because
of the limited number of events (n5 23), was observed between
methylation status in normal lung, particularly in patients with
adenocarcinoma, and development of secondary primary tumors
of the lung during follow-up of the patients.
These results, if validated in larger studies, support the
proposition that FHIT methylation in normal lung tissue could
represent a prognostic marker for progressive disease, and
particularly for assessment of the risk of early recurrence after
surgery.
In conclusion, this multicentric effort of establishing a cen-
tralized European lung tissue bank has facilitated the collection
and sharing of large series of biological specimens and could
prove to be a useful approach to reliably study the role of
a number of different biomarkers with relevance for lung cancer
prognosis or early detection.
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